Loading...
XNAS
BGMS
Market cap4mUSD
Oct 08, Last price  
0.82USD
1D
-3.41%
1Q
-8.85%
Jan 2017
-84.48%
Name

Cyclacel Pharmaceuticals Inc

Chart & performance

D1W1MN
XNAS:BGMS chart
P/E
—
P/S
6.07
EPS
—
Div yield, %
—
Shrs. gr., 5y
364.64%
Rev. gr., 5y
22.87%
Revenues
747k
+1,637.21%
387,000129,000877,000911,000686,000699,00069,0001,084,0001,734,0001,944,000843,0000150,0000000420,00043,000747,000
Net income
-3m
L-73.26%
-29,258,000-24,053,000-40,386,000-19,570,000-16,021,000-15,243,000-13,186,000-10,153,000-19,387,000-14,342,000-11,791,000-7,470,000-7,288,000-7,830,000-8,445,000-18,457,000-21,198,000-22,555,000-11,212,000-2,998,000
CFO
-5m
L-40.30%
-20,172,000-23,140,000-29,905,000-15,193,000-16,044,000-13,977,000-12,043,000-18,199,000-18,702,000-14,460,000-10,079,000-7,480,000-6,701,000-9,447,000-7,934,000-18,540,000-20,827,000-16,112,000-7,990,000-4,770,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.

Key people

Sing Ee Wong
Chief Executive Officer, Executive Director · since 2025
David Lazar
Co-Principal Financial Officer · since 2025
Brian Schwartz
Interim Chief Medical Officer · since 2025
Cu Seng Kiu
Co-Chief Financial Officer, Director · since 2026
Kwang Fock Chong
Independent Director · since 2025
Satis Krishnan
Independent Director · since 2025
Inigo Laurdura
Independent Director · since 2025
Soon Ping Pappas
Independent Director · since 2025
URL
https://bgmsglobal.com/
IPO date
Jan 01, 1996
Employees
12
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
US
Previous name
Xcyte Therapies, Inc.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT